Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

A Case of Therapy-related Myelodysplastic Syndrome after FOLFOX4 Chemotherapy in Advanced Gastric Cancer

  • Kwang Il Seo (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Sung Eun Kim (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Moo In Park (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Seun Ja Park (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Won Moon (Department of Internal Medicine, Kosin University College of Medicine) ;
  • You Jin Han (Department of Internal Medicine, Kosin University College of Medicine)
  • Received : 2016.04.21
  • Accepted : 2016.06.16
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Oxaliplatin is a third-generation platinum compound widely used to treat gastrointestinal malignancy. One of the major side effects of oxaliplatin is thrombocytopenia, the development of which can limit appropriate treatment. We report a 38-year-old man with advanced gastric cancer who developed severe thrombocytopenia after FOLFOX4 (oxaliplatin, leucovorin, and fluorouracil) chemotherapy. The thrombocytopenia was associated with therapy-related myelodysplastic syndrome after cytotoxic chemotherapy and was confirmed by bone marrow biopsy and genetic study. Therefore, physicians should be aware of therapy-related hematologic complications, especially with an oxaliplatin-based chemoregimen, and might consider the bone marrow study in those patients.

Keywords

References

  1. Sill H, Olipitz W, Zebisch A, et al. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol 2011 Feb;162(4):792-805.
  2. Lee CW, Park MI, Park SJ, et al. FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer. Korean J Med 2012;82:37-44.
  3. Jardim DL, Rodrigues CA, Novis YA, Rocha VG, Hoff PM. Oxaliplatin-related thrombocytopenia. Ann Oncol 2012;23(8):1937-1942.
  4. Mundt P, Mochmann HC, Ebhardt H, Zeitz M, Duchmann R, Pauschinger M.. Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer. Oncology 2007;73:270-272.
  5. Churpek JE, Larson RA. The evolving challenge of therapy-related myeloid neoplasm. Best Pract Res Clin Haemato 2013;26(4):309-317.
  6. Bueso-Ramos CE, Kanagal-Shamanna R, Routbort MJ, Hanson CA. Therapy-Related Myeloid Neoplasms. Am J Clin Pathol 2015;144(2):207-218.
  7. Fianchi L, Pagano L, Piciocchi A, Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015;90(5):E80-85.
  8. Larson RA. Cytogenetics, Not Just Previous Therapy, Determines the Course of Therapy-Related Myeloid Neoplasms. J Clin Onco 2012;30(19):2300-2302.